2023
Improving Substance Use Prevention, Assessment, and Treatment Financing to Enhance Equity and Improve Outcomes Among Children, Adolescents, and Young Adults
Camenga D, Hammer L. Improving Substance Use Prevention, Assessment, and Treatment Financing to Enhance Equity and Improve Outcomes Among Children, Adolescents, and Young Adults. 2023, 148-157. DOI: 10.1542/9781610027052-part01-improving.Peer-Reviewed Original Research
2022
Improving Substance Use Prevention, Assessment, and Treatment Financing to Enhance Equity and Improve Outcomes Among Children, Adolescents, and Young Adults.
Camenga DR, Hammer LD. Improving Substance Use Prevention, Assessment, and Treatment Financing to Enhance Equity and Improve Outcomes Among Children, Adolescents, and Young Adults. 2022, 150 PMID: 35757960, DOI: 10.1542/peds.2022-057992.Peer-Reviewed Original Research
2020
Veridical causal inference using propensity score methods for comparative effectiveness research with medical claims
Ross R, Shi X, Caram M, Tsao P, Lin P, Bohnert A, Zhang M, Mukherjee B. Veridical causal inference using propensity score methods for comparative effectiveness research with medical claims. Health Services And Outcomes Research Methodology 2020, 21: 206-228. PMID: 34040495, PMCID: PMC8142944, DOI: 10.1007/s10742-020-00222-8.Peer-Reviewed Original ResearchPropensity score methodsEstimate causal treatment effectsClaims-based studyCausal treatment effectsMedical insurance claimsPrivate payersScoring methodData Mart DatabaseMedical claimsSub-cohortEffectiveness researchPopulation-based inferenceInsurance claimsSelection biasCausal inferenceCompare findingsOnline version
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsAmerican Heart Association’s Call to Action for Payment and Delivery System Reform
Bufalino V, Berkowitz S, Gardner T, Piña I, Konig M, Bauman M, Barbouche M, Creager M, Fonarow G, Gibbons R, Meltzer D, Meltzer N, Schwamm L, Warner J. American Heart Association’s Call to Action for Payment and Delivery System Reform. Circulation 2017, 136: e162-e171. PMID: 28696250, DOI: 10.1161/cir.0000000000000516.Peer-Reviewed Original ResearchConceptsAmerican Heart AssociationHeart AssociationDelivery system reformPatient-centered medical homeExpert panelDelivery system transformationAccountable care organizationsMedical homeHealth professionalsPatient careMedical careInterests of patientsBaseline reviewHealthcare systemCare organizationsParticular medicinePrivate payersAssociationPayment modelsCareDelivery modelAlternative deliverySystem reformFurther involvementPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply